echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > PNAS: Long-acting peptide drug CPT31 to treat AIDS, the future is bright!

    PNAS: Long-acting peptide drug CPT31 to treat AIDS, the future is bright!

    • Last Update: 2020-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the World Health Organization (WHO), about 1.7 million people worldwide will be infected with HIV in 2019.
    more than 38 million people are currently infected with the virus.
    combination of antiretroviral therapy (cART), the so-called "cocktail therapy", has significantly improved the survival and quality of life of such patients, but "cocktail therapy" is also very expensive and has serious side effects.
    addition, drug resistance has been a challenge because of the frequent mutations in HIV, so researchers have been looking for new drugs with novel mechanisms to produce more effective combination therapies.
    researchers at the University of Utah and the National Institute of Allergy and Infectious Diseases (NIAID) recently developed CPT31, a peptide drug that blocks HIV from entering cells, which provides long-term protection for patients with fewer side effects.
    the drug has been tested in non-human primates and may eventually replace or supplement the "cocktail therapy" currently used to prevent or treat AIDS.
    CPT31 is derived from D peptides (a natural peptide) and is specific to the key pockets in the HIV fusion mechanism, and CPT31 does not degrade in vivo.
    , CPT31 has a longer half-life than natural peptides.
    . Michael S. Kay, of the University of Utah, said, "CPT31 represents a new option for the prevention and treatment of AIDS, and CPT31 has a unique mechanism of action with great potential.
    CPT31 can help patients with drug-resistant AIDS."
    the study was recently published in the Proceedings of the National Academy of Sciences (PNAS).
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.